ClinicalTrials.gov
ClinicalTrials.gov Menu

Asthma Control-A "Patient Follow up Programme" Maintenance and Reliever Therapy in a Single Inhaler

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00524641
Recruitment Status : Completed
First Posted : September 3, 2007
Last Update Posted : July 9, 2009
Sponsor:
Information provided by:
AstraZeneca

Brief Summary:
To investigate the change in patient's asthma symptom control using ACQ scores after 4 to 6 weeks of Symbicort Turbuhaler (budesonide/ formoterol) in SMART approach.

Condition or disease
Asthma

Study Type : Observational
Actual Enrollment : 1254 participants
Time Perspective: Prospective
Official Title: A Patient Follow-up Program to Assess Asthma Control in Patients Using Symbicort® as Maintenance and Relief Therapy in a Single Inhaler (Symbicort® SMART: Budesonide/Formoterol 160/4.5 Mcg, 1 or 2 Inhalations x 2 Times Plus Additional Inhalations as Needed)
Study Start Date : July 2007
Actual Primary Completion Date : March 2008
Actual Study Completion Date : April 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Hospital out-patient departments and private clinics in all areas of Vietnam
Criteria

Inclusion Criteria:

  • Asthma patients from both sexes, age 18 or older
  • Have already been on Symbicort SMART treatment
  • Willing to give written informed consents to participate in the program.

Exclusion Criteria:

  • Patients who are not willing to give written informed consent
  • Patients in emergency care for asthma at ICUs or COPD patients are excluded from the program.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00524641


Locations
Vietnam
Research Site
Hanoi, Vietnam
Research Site
Ho Chi Minh City, Vietnam
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Dinh Ngoc SY, MD TB and Lung Disease Hospital, Hanoi
Study Chair: Tran Van Ngoc, MD, PhD Cho Ray Hospital
Study Chair: Nguyen Hong Duc Pharm Ngoc Thach Hospital
Study Chair: Do Van Dung, MD, PhD Ho Chi Minh City Univ of Medicine and Pharmacist

Additional Information:
ClinicalTrials.gov Identifier: NCT00524641     History of Changes
Other Study ID Numbers: NIS-RVN-SYM-2007/1
NIS-R84-AST-2007/3
First Posted: September 3, 2007    Key Record Dates
Last Update Posted: July 9, 2009
Last Verified: July 2009

Keywords provided by AstraZeneca:
Asthma
Symbicort
NIS

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Budesonide, Formoterol Fumarate Drug Combination
Anti-Asthmatic Agents
Respiratory System Agents